Pfizer, Genentech Target Roxane Over Generic Cancer Drug

Law360, New York (December 7, 2012, 5:39 PM EST) -- Pfizer Inc., Genentech Inc. and Astellas Pharma Inc. unit OSI Pharmaceuticals LLC on Friday sued Roxane Laboratories Inc. in Delaware federal court over the generic-drug maker's bid for approval to market a version of the cancer treatment Tarceva for the second time this year.

OSI, Pfizer and Genentech claim that Roxane, a subsidiary of drug giant Boehringer Ingelheim Corp., violated three patents for the nonsmall-cell lung cancer drug when it filed its abbreviated new drug application with the U.S. Food and Drug Administration earlier this year....
To view the full article, register now.